(Q45137031)

9 December 2017

title

Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice (English)

1 reference

9 December 2017

Fumiko Kawasaki

1

1 reference

9 December 2017

Masafumi Matsuda

2

1 reference

9 December 2017

Yukiko Kanda

3

1 reference

9 December 2017

Hiroshi Inoue

4

1 reference

9 December 2017

Kohei Kaku

5

1 reference

9 December 2017

language of work or name

1 reference

2 November 2004

1 reference

American Journal of Physiology - Endocrinology and Metabolism

9 December 2017

published in

1 reference

9 December 2017

volume

288

1 reference

9 December 2017

issue

3

1 reference

9 December 2017

page(s)

E510-8

1 reference

TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus.

9 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00128.2004

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00128.2004

Interactions between insulin resistance and insulin secretion in the development of glucose intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00128.2004

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00128.2004

Obese and diabetes: Two mutant genes causing diabetes-obesity syndromes in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00128.2004

Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00128.2004

Pathogenesis of NIDDM. A balanced overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00128.2004

Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00128.2004

Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00128.2004

Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00128.2004

Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00128.2004

Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00128.2004

Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00128.2004

Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00128.2004

Genetic analysis of obesity-induced diabetes associated with a limited capacity to synthesize insulin in C57BL/KS mice: evidence for polygenic control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00128.2004

Expression of adiponectin receptors in pancreatic beta cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00128.2004

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00128.2004

Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00128.2004

Abnormal splicing of the leptin receptor in diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00128.2004

Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00128.2004

Normalization by insulin treatment of low mitochondrial glycerol phosphate dehydrogenase and pyruvate carboxylase in pancreatic islets of the GK rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00128.2004

PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00128.2004

Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00128.2004

Quantitative analysis of pancreatic proinsulin mRNA in genetically diabetic (db/db) mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00128.2004

Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00128.2004

Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00128.2004

The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00128.2004

Insulin resistance or insulin deficiency. Which is the primary cause of NIDDM?

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00128.2004

Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00128.2004

Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00128.2004

Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00128.2004

10.1152/AJPENDO.00128.2004

21 January 2018

Identifiers

DOI

1 reference

9 December 2017

1 reference